In a report released today, Peter Welford from Jefferies maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €115.00. The company’s shares closed yesterday at $94.00.
According to TipRanks, Welford is a 4-star analyst with an average return of 3.9% and a 51.96% success rate. Welford covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Novo Nordisk, and Novartis.
In addition to Jefferies, Sanofi also received a Buy from Bank of America Securities’s Graham Parry in a report issued today. However, on April 18, J.P. Morgan maintained a Hold rating on Sanofi (Other OTC: SNYNF).
SNYNF market cap is currently $119.6B and has a P/E ratio of 20.21.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sanofi (SNYNF) Company Description:
Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities. This segment also includes all associates whose activities are related to pharmaceuticals. The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for its Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines. The company was founded in 1973 and is headquartered in Paris, France.
Read More on SNYNF:
- Previously announced Zantac settlement worth $100M, Bloomber says
- Sanofi to pay $100M to settle Zantac cancer lawsuits, Bloomberg says
- French Stocks: Sanofi (SAN) to Revamp US Vaccine Operations, Trim Jobs
- IGM Biosciences weakness creates ‘interesting opportunity,’ says Stifel
- IGM Biosciences announces refocusing of Sanofi collaboration
